✦ LIBER ✦

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

✍ Scribed by M Wirth; C Tyrrell; M Wallace; K.P Delaere; M Sánchez-Chapado; J Ramon; J Hetherington; F Pina; C.F Heynes; T.M Borchers; T Morris; A Stone

Book ID: 117263829
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 223 KB
Volume: 58
Category: Article
ISSN: 0090-4295
DOI: 10.1016/s0090-4295(01)01213-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immediate Treatment with Bicalutamide 15

Immediate Treatment with Bicalutamide 150 mg as Adjuvant Therapy Significantly Reduces the Risk of PSA Progression in Early Prostate Cancer

✍ W See; P Iversen; M Wirth; D McLeod; L Garside; T Morris 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Bicalutamide (‘Casodex’) 150 mg as

Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme

✍ Chris J. Tyrrell; Heather Payne; William A. See; David G. McLeod; Manfred P. Wir 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 245 KB

Immediate treatment with bicalutamide re

Immediate treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy

✍ William See; Manfred Wirth; David McLeod; Peter Iversen; Bo-Eric Persson; Kevin 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 169 KB

181 Bicalutamide (‘Casodex’) 150 mg as a

181 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: Analysis at a median follow-up of 5.4 years

✍ M. Wirth; P. Iversen; D. McLeod; W. See; C. Morris; T. Morris; K. Carroll 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Antiandrogen monotherapy in patients wit

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

✍ Peter Iversen; David G. McLeod; William A. See; Thomas Morris; Jon Armstrong; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB

Re: See W, Iversen P, Wirth M, McLeod D,

Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512–8

✍ Andrea Tubaro; Cosimo De Nunzio 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB